1 |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(1): 7-34.
|
2 |
Chinn SB, Myers JN. Oral cavity carcinoma: current management, controversies, and future directions[J]. J Clin Oncol, 2015, 33(29): 3269-3276.
|
3 |
Hedberg ML, Goh G, Chiosea SI, et al. Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma[J]. J Clin Invest, 2016, 126(4): 1606.
|
4 |
Amable L. Cisplatin resistance and opportunities for precision medicine[J]. Pharmacol Res, 2016, 106: 27-36.
|
5 |
Gibson MK, Li Y, Murphy B, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group[J]. J Clin Oncol, 2005, 23(15): 3562-3567.
|
6 |
Clague MJ, Barsukov I, Coulson JM, et al. Deubiquitylases from genes to organism[J]. Physiol Rev, 2013, 93(3): 1289-1315.
|
7 |
Harrigan JA, Jacq X, Martin NM, et al. Deubiquitylating enzymes and drug discovery: emerging opportunities[J]. Nat Rev Drug Discov, 2018, 17(1): 57-78.
|
8 |
Naghavi L, Schwalbe M, Ghanem A, et al. Deubiquitinylase USP47 promotes RelA phosphorylation and survival in gastric cancer cells[J]. Biomedicines, 2018, 6(2): E62.
|
9 |
Amerik AY, Hochstrasser M. Mechanism and function of deubiquitinating enzymes[J]. Biochim Biophys Acta, 2004, 1695(1-3): 189-207.
|
10 |
Pfoh R, Lacdao IK, Saridakis V. Deubiquitinases and the new therapeutic opportunities offered to cancer[J]. Endocr Relat Cancer, 2015, 22(1): T35-T54.
|
11 |
Shi JD, Liu YJ, Xu XH, et al. Deubiquitinase USP47/UBP64E regulates β-catenin ubiquitination and degradation and plays a positive role in wnt signaling[J]. Mol Cell Biol, 2015, 35(19): 3301-3311.
|
12 |
Choi BJ, Park SA, Lee SY, et al. Hypoxia induces epithelial-mesenchymal transition in colorectal cancer cells through ubiquitin-specific protease 47-mediated stabilization of Snail: a potential role of Sox9[J]. Sci Rep, 2017, 7(1): 15918.
|
13 |
Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Allen C, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: asystematic analysis for the global burden of disease study[J]. JAMA Oncol, 2017, 3(4): 524-548.
|
14 |
Mansouri A, Zhang QX, Ridgway LD, et al. Cisplatin resistance in an ovarian carcinoma is associated with a defect in programmed cell death control through XIAP regulation[J]. Oncol Res, 2003, 13(6): 399-404.
|
15 |
Qian H, Huang T, Chen Y, et al. X-linked inhibitor of apoptosis protein inhibitor Embelin induces apoptosis via PI3K/Akt pathway and inhibits invasion in osteosarcoma cells[J]. J Cancer Res Ther, 2018, 14(): S648-S655.
|
16 |
DPDCTirapelli, Lustosa IL, Menezes SB, et al. High expression of XIAP and Bcl-2 may inhibit programmed cell death in glioblastomas[J]. Arq Neuropsiquiatr, 2017, 75(12): 875-880.
|
17 |
Yang TW, Gao YX, Liu DJ, et al. ASPP2 enhances chemotherapeutic sensitivity through the down-regulation of XIAP expression in a p53 independent manner in hepatocellular carcinoma[J]. Biochem Biophys Res Commun, 2019, 508(3): 769-774.
|
18 |
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation[J]. Cell, 2011, 144(5): 646-674.
|
19 |
Yang XK, Zheng F, Xing H, et al. Resistance to chemotherapy-induced apoptosis via decreased caspase-3 activity and overexpression of antiapoptotic proteins in ovarian cancer[J]. J Cancer Res Clin Oncol, 2004, 130(7): 423-428.
|
20 |
Williams J, Lucas PC, Griffith KA, et al. Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease[J]. Gynecol Oncol, 2005, 96(2): 287-295.
|